[go: up one dir, main page]

WO2002003998A3 - Macrolide formulations for inhalation and methods of treatment of endobronchial infections - Google Patents

Macrolide formulations for inhalation and methods of treatment of endobronchial infections Download PDF

Info

Publication number
WO2002003998A3
WO2002003998A3 PCT/US2001/041328 US0141328W WO0203998A3 WO 2002003998 A3 WO2002003998 A3 WO 2002003998A3 US 0141328 W US0141328 W US 0141328W WO 0203998 A3 WO0203998 A3 WO 0203998A3
Authority
WO
WIPO (PCT)
Prior art keywords
erythromycylamine
formulation
treatment
methods
macrolide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/041328
Other languages
French (fr)
Other versions
WO2002003998A2 (en
Inventor
William R Baker
Peter B Challoner
Ribhi M Shawar
Kay K Huh
David M Rycman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ523693A priority Critical patent/NZ523693A/en
Priority to US10/333,948 priority patent/US20040022740A1/en
Priority to KR10-2003-7000412A priority patent/KR20030020924A/en
Priority to EP01962298A priority patent/EP1309332A2/en
Priority to MXPA03000321A priority patent/MXPA03000321A/en
Priority to BR0112330-0A priority patent/BR0112330A/en
Priority to CA002415498A priority patent/CA2415498A1/en
Priority to AU2001283491A priority patent/AU2001283491B2/en
Priority to IL15387501A priority patent/IL153875A0/en
Priority to JP2002508452A priority patent/JP2004502736A/en
Priority to AU8349101A priority patent/AU8349101A/en
Application filed by Chiron Corp filed Critical Chiron Corp
Publication of WO2002003998A2 publication Critical patent/WO2002003998A2/en
Publication of WO2002003998A3 publication Critical patent/WO2002003998A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Macrolide formulations, such as an erythromycylamine formulation, for delivery by aerosolization are described. The concentrated erythromycylamine formulations contain an amount of erythromycylamine effective to treat infections caused by susceptible bacteria. Unit dose devices having a container containing a formulation of the macrolide antibiotic in a physiologically acceptable carrier are also described. Methods for treatment of pulmonary infections by a formulation (liquid solution, suspension, or dry powder) delivered as an aerosol having mass median aerodynamic diameter predominantly between 1 to 5 νm are also described.
PCT/US2001/041328 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections Ceased WO2002003998A2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
NZ523693A NZ523693A (en) 2000-07-10 2001-07-01 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU2001283491A AU2001283491B2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
EP01962298A EP1309332A2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
MXPA03000321A MXPA03000321A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections.
BR0112330-0A BR0112330A (en) 2000-07-10 2001-07-10 Inhalation macrolides formulations and their uses for the treatment of endobronchial infections
CA002415498A CA2415498A1 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
JP2002508452A JP2004502736A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treating endobronchial infections
US10/333,948 US20040022740A1 (en) 2001-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
IL15387501A IL153875A0 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
AU8349101A AU8349101A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections
KR10-2003-7000412A KR20030020924A (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21703200P 2000-07-10 2000-07-10
US60/217,032 2000-07-10

Publications (2)

Publication Number Publication Date
WO2002003998A2 WO2002003998A2 (en) 2002-01-17
WO2002003998A3 true WO2002003998A3 (en) 2002-06-13

Family

ID=22809403

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/041328 Ceased WO2002003998A2 (en) 2000-07-10 2001-07-10 Macrolide formulations for inhalation and methods of treatment of endobronchial infections

Country Status (11)

Country Link
EP (1) EP1309332A2 (en)
JP (1) JP2004502736A (en)
KR (1) KR20030020924A (en)
CN (1) CN1202831C (en)
AU (2) AU2001283491B2 (en)
BR (1) BR0112330A (en)
CA (1) CA2415498A1 (en)
IL (1) IL153875A0 (en)
MX (1) MXPA03000321A (en)
NZ (1) NZ523693A (en)
WO (1) WO2002003998A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003225689B2 (en) * 2002-03-05 2009-03-26 Transave, Inc. Methods for entrapment of bioactive agent in a liposome or lipid complex
AU2003205499A1 (en) * 2003-02-28 2004-09-17 Anbics Patents-Licences Ag Method for treatment and prevention of acute and chronic pseudomonas aeruginosa airway infections with inhalable macrolides
WO2004080391A2 (en) 2003-03-10 2004-09-23 Optimer Pharmaceuticals, Inc. Novel antibacterial agents
MXPA05013324A (en) * 2003-06-10 2006-03-09 Astellas Pharma Inc AEROSOL PREPARATION UNDERSTANDING AN ANNEX THAT INCLUDES A COMPOSITION OF AEROSOL CONTAINING MACROLID COMPOUND.
US20050266578A1 (en) * 2004-05-06 2005-12-01 Gruenke Larry D Methods and systems for detection of macrolides
ATE493969T1 (en) 2004-05-17 2011-01-15 Corus Pharma Inc COMBINATION OF FOSFOMYCIN/AMINOGLYCOSIDE IN AEROSOL FORM FOR THE TREATMENT OF BACTERIAL RESPIRATORY INFECTIONS
CA2665764C (en) * 2006-10-11 2015-05-26 Laboratoires Smb S.A. Pharmaceutical anti-infective composition for inhalation
EP2030644A1 (en) 2007-08-31 2009-03-04 PARI Pharma GmbH Aerosols for sinunasal drug delivery
US9453042B2 (en) 2007-10-25 2016-09-27 Cempra Pharmaceuticals, Inc. Process for the preparation of macrolide antibacterial agents
EP2098219A1 (en) * 2008-03-05 2009-09-09 PARI Pharma GmbH Macrolide compositions having improved taste and stability
CN102245195B (en) 2008-10-24 2016-01-13 森普拉制药公司 Biodefense using triazole-containing macrolides
US9937194B1 (en) 2009-06-12 2018-04-10 Cempra Pharmaceuticals, Inc. Compounds and methods for treating inflammatory diseases
PL2544537T3 (en) * 2010-03-10 2017-10-31 Cempra Pharmaceuticals Inc Parenteral formulations of macrolide antibiotics
CA2799937A1 (en) 2010-05-20 2011-11-24 Cempra Pharmaceuticals, Inc. Processes for preparing macrolides and ketolides and intermediates therefor
JP6042334B2 (en) 2010-09-10 2016-12-14 センプラ ファーマシューティカルズ，インコーポレイテッド Hydrogen bond forming fluoroketolides for disease treatment
SG11201405895UA (en) 2012-03-27 2014-10-30 Cempra Pharmaceuticals Inc Parenteral formulations for administering macrolide antibiotics
RU2015138796A (en) 2013-03-14 2017-04-19 Семпра Фармасьютикалс, Инк. METHODS AND COMPOSITIONS FOR TREATMENT OF RESPIRATORY DISEASES
HK1218864A1 (en) 2013-03-15 2017-03-17 森普拉制药公司 Convergent processes for preparing macrolide antibacterial agents
FI20205368A1 (en) * 2020-04-07 2021-10-08 Aalto Univ Foundation Sr FORMULATION
CN114796116A (en) * 2022-05-17 2022-07-29 中山大学附属第六医院 Azithromycin inhalant and preparation method thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
WO1995015182A1 (en) * 1993-12-02 1995-06-08 Emory University Antiinfective compositions and methods of use
WO1995025510A1 (en) * 1994-03-18 1995-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
EP0700678A1 (en) * 1994-07-13 1996-03-13 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
WO1996037190A1 (en) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmedica Gmbh Stable, concentrated, locally-tolerated erythromycylamine solutions
WO2000015207A2 (en) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
WO2000035408A2 (en) * 1998-12-18 2000-06-22 Pathogenesis Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60209517A (en) * 1984-04-03 1985-10-22 Unitika Ltd Aerosol composition
IE63869B1 (en) * 1986-11-06 1995-06-14 Res Dev Foundation Aerosols containing liposomes and method for their preparation
JPH01283225A (en) * 1988-05-10 1989-11-14 Toyo Jozo Co Ltd Aerosol preparation for treating infectious disease of bovine respiratory organ and treating method using the same
DE69814428T2 (en) * 1997-09-29 2004-05-13 Nektar Therapeutics, San Carlos PREPARED, STABILIZED PREPARATIONS
HRP20010141A2 (en) * 1998-08-28 2002-02-28 Lilly Co Eli Method for administering insulinotropic peptides
IT1303692B1 (en) * 1998-11-03 2001-02-23 Chiesi Farma Spa PROCEDURE FOR THE PREPARATION OF SUSPENSIONS OF PARTICLES OF DRUGS TO BE ADMINISTERED BY INHALATION.
CN1348377A (en) * 1998-12-17 2002-05-08 希龙公司 Method for the treatment of severe chronic bronchitis (bronchiectasis) with an aerosolized antibiotic

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990006775A1 (en) * 1988-12-14 1990-06-28 Liposome Technology, Inc. A novel nonphospholipid liposome composition for sustained release of drugs
WO1995015182A1 (en) * 1993-12-02 1995-06-08 Emory University Antiinfective compositions and methods of use
WO1995025510A1 (en) * 1994-03-18 1995-09-28 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Pharmaceutical compositions containing alkylthioalkanoic acids or derivatives thereof and their use in the treatment of mycobacterial infections and as antiseptic
EP0700678A1 (en) * 1994-07-13 1996-03-13 Wakamoto Pharmaceutical Co., Ltd. Stable lipid emulsion
WO1996037190A1 (en) * 1995-05-23 1996-11-28 Boehringer Ingelheim Vetmedica Gmbh Stable, concentrated, locally-tolerated erythromycylamine solutions
WO2000015207A2 (en) * 1998-09-15 2000-03-23 Naeja Pharmaceutical Inc. Combination for the treatment of inflammation using elastine inhibitor(s) and antibacterial agent(s)
WO2000035408A2 (en) * 1998-12-18 2000-06-22 Pathogenesis Corporation Method for treatment of bacterial infections with once or twice-weekly administered rifalazil
US6156294A (en) * 1999-11-28 2000-12-05 Scientific Development And Research, Inc. Composition and method for treatment of otitis media

Also Published As

Publication number Publication date
JP2004502736A (en) 2004-01-29
BR0112330A (en) 2003-10-07
NZ523693A (en) 2004-08-27
IL153875A0 (en) 2003-07-31
CN1202831C (en) 2005-05-25
AU8349101A (en) 2002-01-21
WO2002003998A2 (en) 2002-01-17
MXPA03000321A (en) 2003-06-06
CN1471401A (en) 2004-01-28
AU2001283491B2 (en) 2007-02-15
KR20030020924A (en) 2003-03-10
EP1309332A2 (en) 2003-05-14
CA2415498A1 (en) 2002-01-17

Similar Documents

Publication Publication Date Title
WO2002003998A3 (en) Macrolide formulations for inhalation and methods of treatment of endobronchial infections
DE60210402D1 (en) System for delivering a tobramycin formulation
GR3031770T3 (en) Novel and improved aminoglycoside formulation for aerosolization
CA2369722A1 (en) Powder inhaler for combined medicament
MY121789A (en) Closure-cap and container as a two-chamber cartridge for nebulisers for producing aerosols and active substance formulations, suitable for storage
WO2001049274A3 (en) Methods for pulmonary delivery of interleukin-2
LV12586A (en) Aerosolized active agent delivery
CA2049302A1 (en) Aerosol carriers
PL317225A1 (en) Drugs
CA2346791A1 (en) Flow resistance modulated aerosolized active agent delivery
IL149085A0 (en) A dry powder composition containing a di or tripeptide
WO2007067520A3 (en) Lipid-based compositions of antiinfectives for treating pulmonary infections
CA2322434A1 (en) Medicament delivery and packaging
CA2277913A1 (en) New formulation for inhalation having a poured bulk density of 0.28 to 0.38 g/ml, a process for preparing the formulation and the use thereof
WO2002043750A3 (en) Method for the stabilizing of biomolecules (e.g. insulin) in liquid formulations
CA2445516A1 (en) Metered dose delivery device for liquid and powder agents
CA2981038A1 (en) Dry powder vancomycin compositions and associated methods
CA2564546A1 (en) Aerosolized fosfomycin/aminoglycoside combination for the treatment of bacterial respiratory infections
WO2002024261A3 (en) Shock wave aerosolization apparatus and method
WO2005037256A3 (en) Liquid preparation containing tobramycin
BR0303347A (en) Aerosol formulations containing esters of 3,17-dihydroxy stratiene derivatives for pulmonary deposition

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 153875

Country of ref document: IL

Ref document number: 2415498

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020037000412

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2001283491

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 523693

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001962298

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 018141218

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 1020037000412

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001962298

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2003115433

Country of ref document: RU

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 10333948

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 523693

Country of ref document: NZ

WWG Wipo information: grant in national office

Ref document number: 523693

Country of ref document: NZ